Skip to main content

Table 2 Pharmacokinetic parameters for pantoprazole, rabeprazole, and omeprazole administered under fasting and fed conditions, considering only CYP2C19*1/*1 subjects. Data are expressed as mean ± standard deviation. *p ≤ 0.05 vs. men

From: Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

  n AUC0-∞ (ng·h/ml) Cmax (ng/ml) Tmax (h) t1/2 (h) Vd/F (l/kg) Cl/F (L/h·kg) Ke
Pantoprazole (n = 28)
Fast 14 6085.3 ± 2922.6 2539.7 ± 836.3 3.0 ± 0.7 1.2 ± 0.4 0.18 ± 0.03 0.12 ± 0.05 0.64 ± 0.19
  Men 8 4780.9 ± 2471.8 2019.8 ± 492.8 3.0 ± 0.7 1.3 ± 0.5 0.20 ± 0.02 0.14 ± 0.06 0.64 ± 0.23
  Women 6 7824.6 ± 2702.2 3233.0 ± 685.0 2.9 ± 0.8 1.1 ± 0.2 0.16 ± 0.04 0.11 ± 0.04 0.63 ± 0.12
Fed 14 4689.0 ± 2303.3 2660.7 ± 531.2 5.7 ± 1.2 1.2 ± 0.5 0.24 ± 0.05 0.16 ± 0.07 0.67 ± 0.20
  Men 8 4520.4 ± 2518.4 2564.3 ± 581.1 5.3 ± 1.1 1.2 ± 0.6 0.23 ± 0.03 0.15 ± 0.07 0.67 ± 0.25
  Women 6 4913.8 ± 2192.7 2789.3 ± 475.5 6.2 ± 1.1 1.1 ± 0.3 0.25 ± 0.06 0.17 ± 0.08 0.68 ± 0.14
Fed vs. Fast
ratio; 90% CI; p value
74.8; 55.8–100.1
p = 0.1010
103.5; 91.3–117.2
p = 0.6431
192.2; 166.5–221.9
p = 0.001
95.6; 76.7–119.0
p = 0.7262
127.5; 113.2–143.6
p = 0.0018
129.1; 96.7–172.3
p = 0.1439
104.6; 84.0–130.3
p = 0.7262
Rabeprazole (n = 23)
Fast 14 901.2 ± 234.6 536.3 ± 138.2 3.9 ± 0.8 1.3 ± 0.6 0.60 ± 0.11 0.37 ± 0.09 0.63 ± 0.20
  Men 7 870.2 ± 295.6 512.2 ± 146.8 3.9 ± 1.0 1.5 ± 0.7 0.59 ± 0.10 0.33 ± 0.10 0.57 ± 0.25
  Women 7 932.2 ± 172.0 560.4 ± 135.8 3.8 ± 0.7 1.1 ± 0.2 0.61 ± 0.12 0.41 ± 0.07 0.68 ± 0.13
Fed 9 968.9 ± 387.5 606.3 ± 206.8 9.1 ± 3.3 2.0 ± 0.9 0.92 ± 0.34 0.38 ± 0.18 0.45 ± 0.23
  Men 4 999.7 ± 322.7 572.2 ± 215.1 10.3 ± 5.1 2.5 ± 0.7 1.02 ± 0.39 0.30 ± 0.11 0.30 ± 0.11
  Women 5 944.2 ± 469.6* 633.6 ± 220.7 8.2 ± 0.6 1.5 ± 0.9* 0.85 ± 0.32 0.45 ± 0.20* 0.57 ± 0.25*
Fed vs. Fast 104.5; 82.7–131.9
p = 0.7488
111.7; 89.5–139.2
p = 0.3987
228.8; 187.0–278.9
p = 0.0001
152.0; 113.4–203.7
p = 0.023
147.6; 121.6–179.3
p = 0.0025
94.7; 75.1–119.5
p = 0.6913
65.8; 49.1–88.2
p = 0.023
Omeprazole (n = 36)
Fast 15 1709.0 ± 1299.6 859.5 ± 394.9 1.8 ± 0.6 1.0 ± 0.4 0.69 ± 0.38 0.57 ± 0.39 0.81 ± 0.23
  Men 8 1474.9 ± 1403.1 654.1 ± 305.6 2.0 ± 0.7 0.9 ± 0.4 0.68 ± 0.46 0.62 ± 0.44 0.82 ± 0.25
  Women 7 1976.5 ± 1219.8 1094.3 ± 366.6 1.5 ± 0.3 1.0 ± 0.3 0.69 ± 0.46 0.53 ± 0.36 0.79 ± 0.23
Fed 16# 1523.3 ± 1290.5 604.4 ± 362.6 4.7 ± 1.0 1.0 ± 0.4 0.77 ± 0.43 0.62 ± 0.41 0.80 ± 0.36
  Men 10 1409.7 ± 1162.1 582.8 ± 419.1 4.3 ± 1.0 1.0 ± 0.4 0.73 ± 0.38 0.63 ± 0.49 0.84 ± 0.39
  Women 6 1712.7 ± 1250.2 640.4 ± 275.1 5.4 ± 0.4 1.1 ± 0.4 0.84 ± 0.54 0.57 ± 0.29 0.72 ± 0.32
Fed vs. Fast
ratio; 90% CI; p value
88.5; 82.4–95.1
p = 0.0101
64.3; 52.5–78.7
p = 0.0019
278.3; 227.7–340.1
p = 0.0001
104.8; 87.7–125.3
p = 0.6457
118.9; 93.3–151.5
p = 0.2271
115.3; 105.3–126.2
p = 0.0159
95.4; 79.8–114.0
p = 0.6457
  1. #15 of the subjects participated in both fast and fed omeprazole clinical trials